Group 1 - A-shares and Hong Kong stocks in the innovative pharmaceutical sector have rebounded, with significant gains in related stocks and ETFs [1][3][5] - The largest medical ETF in A-shares (512170) saw a trading volume of 589 million yuan, recovering 1.34% on the day [1] - The innovative drug sector is experiencing a collective rise, with notable stocks like Huahai Pharmaceutical increasing by 7.59% [3] Group 2 - The Hong Kong innovative drug ETF (520880) rose by 2.12%, with 35 out of 37 constituent stocks gaining, led by Green Leaf Pharmaceutical with an 8.31% increase [5][7] - Recent funding trends indicate a significant inflow into the innovative drug sector, with over 1.29 billion yuan added in the last three days [7] - Upcoming catalysts include the European Society for Medical Oncology (ESMO) annual meeting, which may showcase significant research results from Chinese innovative drugs [7] Group 3 - Investment strategies suggest focusing on innovative drugs, with specific ETFs like the Hong Kong innovative drug ETF (520880) and the A-share drug ETF (562050) highlighted for their potential [8] - The medical ETF (512170) is noted for its inclusion of CXO companies, which account for 26.77% of its weight [8] - The medical ETF is the largest in the market, with a scale of 26.4 billion yuan, while the drug ETF is the only one tracking the China Pharmaceutical Index [9]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002653 证券简称：海思科 公告编号：2025-111 海思科医药集团股份有限公司 关于获得创新药HSK45019片IND申请《受理通知书》的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 海思科医药集团股份有限公司（以下简称"公司"）子公司上海海思盛诺医药科技有限公司于近日收到国 家药品监督管理局下发的《受理通知书》，基本情况如下： ■ 根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以受理。 一、研发项目简介 炎症性肠病（IBD）是一组慢性胃肠道非特异性炎性疾病，包括溃疡性结肠炎（UC）和克罗恩病 （CD），主要临床表现包括腹痛、腹泻、黏液脓血便、瘘管以及肛周病变，病情缓解与复发交替，可 伴随患者终生。IBD常用的治疗药物有氨基水杨酸、激素、硫唑嘌呤、环孢素、沙利度胺等传统制剂， 以及英夫利昔单抗、阿达木单抗、维得利珠单抗等生物制剂，但这些治疗对很大一部分患者疗效不佳， 或因不良反应太大导致患者无法耐受。对于难治性IBD，患者亟需有效的替代方案。由于目前对IBD免 疫发病 ...

（文章来源：证券日报） 证券日报网讯 10月13日晚间，海思科发布公告称，公司子公司上海海思盛诺医药科技有限公司于近日 收到国家药品监督管理局下发的《受理通知书》，药品名称为HSK50042片，申请事项为境内生产药品 注册临床试验。 ...

（文章来源：证券日报） 证券日报网讯 10月13日晚间，海思科发布公告称，公司子公司上海海思盛诺医药科技有限公司于近日 收到国家药品监督管理局下发的《受理通知书》，药品名称为HSK55718，申请事项为境内生产药品注 册临床试验。 ...

（文章来源：证券日报） 证券日报网讯 10月13日晚间，海思科发布公告称，公司子公司上海海思盛诺医药科技有限公司于近日 收到国家药品监督管理局下发的《受理通知书》，涉及药品名称为HSK45019片，申请事项为境内生产 药品注册临床试验。 ...

北京商报讯(记者丁宁)10月13日晚间，海思科（002653）发布公告称，公司于10月13日获悉， HSK39297片正式被国家药品监督管理局药品审评中心(CDE)纳入《突破性治疗品种名单》。海思科表 示，HSK39297片在纳入突破性治疗后，将极大的推动该领域新药的研发历程，为我国肾脏/泌尿系统疾 病的治疗带来新的希望。 公告显示，HSK39297是海思科自主研发的一种口服、强效和高选择性的补体因子B小分子抑制剂。临 床拟用于治疗补体参与介导的溶血性疾病及补体参与介导的原发性或继发性肾小球疾病等。 ...

Group 1 - Harbin Air Conditioning plans to transfer 40% equity of its subsidiary, Harbin Fushanchuan Biotechnology Development Co., Ltd. The subsidiary reported a net profit of -16.0963 million yuan for 2024, which is 218.83% of the previous year's net profit absolute value [1] - Xinhua Insurance expects a net profit of 29.986 billion to 34.122 billion yuan for the first three quarters of 2025, representing a year-on-year growth of 45% to 65% [1][2] - Gansu Energy anticipates a net profit of 1.55 billion to 1.6 billion yuan for the first three quarters of 2025, reflecting a year-on-year increase of 11.86% to 15.47% [2][3] Group 2 - Dongfang Tower forecasts a net profit of 750 million to 900 million yuan for the first three quarters of 2025, indicating a year-on-year growth of 60.83% to 93% [4] - Meili Eco announced that its subsidiary won a bid for an EPC project worth 2.375 billion yuan [6] - Bohai Chemical's wholly-owned subsidiary will undergo routine maintenance for its 600,000 tons/year PDH unit, expected to last about 30 days [8] Group 3 - Qin Port Co. reported a total throughput of 317.02 million tons for the first nine months of 2025, a year-on-year increase of 5.56% [10] - Jianglong Shipbuilding won a bid for a 72.99 million yuan fishery enforcement vessel project, accounting for 4.22% of its 2024 audited revenue [11] - Longyuan Technology expects a net profit of 35 million to 40 million yuan for the first three quarters of 2025, representing a year-on-year increase of 50.11% to 71.55% [12] Group 4 - Naipu Mining anticipates a net profit of 61 million to 66 million yuan for the first three quarters of 2025, reflecting a year-on-year decline of 45.16% to 49.32% [14] - Jinggong Steel Structure reported a cumulative contract amount of 17.98 billion yuan for the first nine months of 2025, a year-on-year increase of 4.8% [15][16] - Shenzhen Gas reported a net profit of 918 million yuan for the first three quarters of 2025, a year-on-year decrease of 13.08% [17] Group 5 - Yabao Pharmaceutical's subsidiary received a drug registration certificate for a new diabetes medication [18] - Shaanxi Coal's coal production in September was 14.56 million tons, a year-on-year increase of 5.34% [20] - Sifang New Materials reported a 15.94% year-on-year decline in concrete production for the first three quarters [22] Group 6 - Nanjing Foods reported a consolidated revenue of 276 million yuan in September, a slight increase of 0.0016% year-on-year [23] - Pulaike received a new veterinary drug registration certificate for a flea and tick treatment [24] - Zhucheng Technology received a cash dividend of 15 million yuan from its subsidiary [25] Group 7 - David Medical's subsidiary received a medical device registration certificate for a portable electronic endoscope image processor [26] - Zhongtong Bus reported a 36.88% year-on-year increase in sales in September, totaling 1,106 units [27] - Xiantan Co. reported a 11.95% year-on-year increase in chicken sales revenue in September [28] Group 8 - Bojun Technology expects a net profit of 552 million to 662 million yuan for the first three quarters of 2025, a year-on-year increase of 50% to 80% [30] - Haishi Pharmaceutical's innovative pain relief drug clinical trial application has been accepted [31] - Lingxiao Pump Industry used 80 million yuan of idle funds to purchase financial products [32] Group 9 - Qiangda Circuit's subsidiary completed business registration changes to expand its operational scope [33] - *ST Tianyu's controlling shareholder applied for bankruptcy liquidation due to severe financial difficulties [34] - Baolidi's shareholder plans to reduce holdings by up to 1 million shares [36] Group 10 - Zijin Mining completed the acquisition of Kazakhstan's Raygorodok gold mine, controlling 100% of its rights [44] - Zhonggang Luoyang's indirect controlling shareholder completed a capital increase, raising registered capital from approximately 26.666 billion yuan to 44.824 billion yuan [46] - Jinyu Jidong's director resigned due to work adjustments [47]

HSK45019是公司自主研究，具有独立知识产权的小分子抑制剂，HSK45019有望为炎症性肠病患者提供 一种新颖的治疗方法，带来更便捷和有效的治疗选择。根据国家药品监督管理局关于发布《化学药品注 册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定，本品属于化学药品1类。 海思科（002653）(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到国家 药品监督管理局下发的《受理通知书》，涉及药品："HSK45019片"。 ...

智通财经APP讯，海思科(002653.SZ)发布公告，公司子公司上海海思盛诺医药科技有限公司于近日收到 国家药品监督管理局下发的《受理通知书》，涉及药品："HSK45019片"。 HSK45019是公司自主研究，具有独立知识产权的小分子抑制剂， HSK45019有望为炎症性肠病患者提 供一种新颖的治疗方法，带来更便捷和有效的治疗选择。根据国家药品监督管理局关于发布《化学药品 注册分类及申报资料要求》的通告(2020年第44号)中化学药品注册分类的规定，本品属于化学药品1 类。 ...

格隆汇10月13日丨海思科(002653.SZ)公布，子公司上海海思盛诺医药科技有限公司于近日收到国家药 品监督管理局下发的《受理通知书》，药品名称：HSK45019片。HSK45019是公司自主研究，具有独立 知识产权的小分子抑制剂，HSK45019有望为炎症性肠病患者提供一种新颖的治疗方法，带来更便捷和 有效的治疗选择。 ...